Bolt Biotherapeutics, Inc. has announced its financial results for the third quarter ended September 30, 2026. This update is significant as it showcases the company's performance and strategic direction in the pharmaceutical sector.

Background

Bolt Biotherapeutics, Inc. operates under the SIC code 2834, which covers Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol BOLT. It is categorized as a non-accelerated filer, smaller reporting company, and an emerging growth company. The company is incorporated in Delaware and has its principal office located in Redwood City, California.

What the Filing Says

According to the filing dated November 12, 2026, Bolt Biotherapeutics issued a press release announcing its financial results for the third quarter. The filing states, "On November 12, 2026, Bolt Biotherapeutics, Inc. (the 'Company') issued a press release announcing its financial results for the third quarter ended September 30, 2026 and a business update." A copy of the press release is included as Exhibit 99.1.

Impact

This financial update may affect various stakeholders, including investors, analysts, and competitors within the pharmaceutical preparations industry. As Bolt Biotherapeutics continues to navigate its financial landscape, the results could influence investor sentiment and competitive positioning.

What's Next

The filing does not say what happens next.